Developer docs
API playgroundTry for free, no card

Search company profiles

Accel Research Sites

Full company profile

uuid000furs

Namestring
Accel Research Sites
Legal namestring
Accel Research Sites
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Accel Research Sites, doing business as Alcanza Clinical Research, is a private clinical research site network founded in 1998 and headquartered in Florida. The company operates 26+ dedicated clinical research facilities across the Southeast, Northeast, Midwest, and Southwest United States, plus Puerto Rico (Mayagüez and San Juan), providing trial execution services in more than 30 therapeutic areas including Alzheimer's disease, oncology, diabetes, vaccines, dermatology, cardiology, and women's health. Accel serves two primary customer segments: pharmaceutical sponsors and Contract Research Organizations (CROs), which contract the network to conduct clinical trials; and patient volunteers, who are recruited through a community-based GTM model that combines website registration, medical provider referrals, and outreach to community-based organizations. The company emphasizes inclusive research participation across diverse demographic populations, supported by multilingual website access in eight languages (English, Spanish, French, German, Italian, Dutch, Chinese, and Arabic).

The company's core technology is the ReachOne AI Toolbox, a wholly-owned subsidiary product positioned as an AI-powered platform for clinical research operations with integration/interoperability as its cited differentiator. ReachOne supplements the primary professional-services revenue stream, which is generated through per-study fees from sponsors and CROs for patient recruitment, study execution, and data collection. Accel is a founding member of the Association of Multisite Research Corporations (AMRC), launched in 2024 as a 14-organization alliance encompassing 400+ research sites, nearly 1,000 Principal Investigators, and more than 7,000 research professionals that collectively enrolled over 73,500 patients in 2024. No external funding rounds, M&A activity, or institutional ownership are disclosed in the available source material, and the company appears to operate as an independently-run private entity.

Short descriptiontext

Accel Research Sites (dba Alcanza Clinical Research) operates a 26+ location network of multi-therapeutic clinical research sites across the US and Puerto Rico, serving pharmaceutical sponsors and CROs with patient recruitment, trial execution, and the ReachOne AI Toolbox.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLake Mary, United States
HQ citystring
Lake Mary
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices31 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, clinical trial network, multisite research, patient recruitment, therapeutic trials
Industry2 codes
PRIMARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code1 code
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

Revenue generated from conducting clinical trials on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). Services include patient recruitment, study execution, and data collection for drug development programs.

alcanzaclinical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Patient volunteer compensation for participation
ModelOtherBilling cadencePay-as-you-go
Notes

Most studies offer payment or compensation for time and travel. No insurance is required for participation.

alcanzaclinical.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1ReachOne AI Toolbox
Description

AI-powered clinical research tools and platform technology

alcanzaclinical.com
Core offering1 text field

Accel Research Sites (operating as Alcanza Clinical Research) is a multi-therapeutic network of dedicated clinical research sites that conduct clinical trials on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). The company delivers patient recruitment, study execution, and data collection services across a broad range of therapeutic areas, including Alzheimer's, diabetes, vaccines, oncology, and chronic conditions, through a community-based model spanning 26+ dedicated research facilities across the United States and Puerto Rico.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 73,500 patients enrolled in clinical trials in 2024 through AMRC network
Product overview1 text field

Alcanza Clinical Research operates as a clinical research site network offering a unified platform for clinical trial participation. The core product is their clinical research services network, supplemented by the ReachOne AI Toolbox for technology-enabled research capabilities. They provide local communities with opportunities to participate in clinical research at dedicated facilities across multiple states, collaborating with medical providers and community organizations.

Product and service1 record
1Alcanza Clinical Research
CategoryClinical Research Site Network
Description

Clinical research site network providing health education and clinical research participation options to diverse patient populations across multiple therapeutic areas. Operates dedicated clinical research facilities across the United States and Puerto Rico, collaborating with medical providers and community-based organizations to deliver clinical trial opportunities for pharmaceutical sponsors and CROs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Association of Multisite Research Corporations (AMRC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Alcanza Clinical Research is a founding member of AMRC, a newly launched alliance of 14 prominent multisite research organizations. AMRC aims to transform clinical trial operations across the U.S. with a network of over 400 research sites, nearly 1,000 Principal Investigators, and over 7,000 research professionals. In 2024, AMRC members collectively enrolled over 73,500 patients into clinical trials. The alliance focuses on minimizing delays impacting 80% of clinical trials, improving operational efficiency, and strengthening collaboration and data quality.

alcanzaclinical.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Multisite clinical research organization operating dedicated research facilities with multi-therapeutic enrollment. Directly comparable SMO competing in the same sponsor-RFP environment as Accel Research Sites.

TypeDirect peer
Description

Multi-therapeutic integrated clinical research site network operating dedicated research facilities across the US. Directly comparable to Accel on SMO business model, multi-therapeutic scope, geographic dispersion, and sponsor/CRO customer base.

TypeBroad incumbent
Description

Global CRO with site-management, clinical operations, and lab services at scale. Competes head-to-head with Accel for site-network selection on multi-region sponsor trials, though from a much broader service portfolio.

TypeBroad incumbent
Description

Mid-to-large CRO specializing in operational delivery of clinical trials across therapeutic areas. Comparable on the clinical-operations and Phase II/III execution layer where Accel provides site capacity, but operates without a dedicated owned-site footprint of Accel's scale.

TypeDirect peer
Description

Mid-size global CRO with site-management and clinical operations offerings. Comparable to Accel on customer base (small-to-mid-biotech sponsors), therapeutic breadth, and professional-services revenue model.

TypeBroad incumbent
Description

Largest global CRO with an integrated site-management and clinical operations platform. Overlaps with Accel on clinical research service delivery but competes from full-service portfolio leverage — directly bidding against Accel for sponsor master agreements.

TypeBroad incumbent
Description

Global CRO offering clinical operations, site management, regulatory, and biopharma services. Comparable to Accel on the sponsor-customer side and on clinical trial execution, though from a far broader full-service delivery model.

TypeBroad incumbent
Description

Global CRO with embedded site-network and decentralized-trial capabilities. Comparable across clinical operations and site management, broader portfolio across commercial and consulting services beyond Accel's narrower SMO scope.

TypeDirect peer
Description

Mid-size full-service CRO with embedded site management capabilities, serving similar small-to-mid-biotech sponsors as Accel. Comparable on therapeutic scope, sponsor-customer profile, and clinical operations delivery model.

TypeDirect peer
Description

Integrated multi-specialty clinical research site organization running dedicated Phase I-IV sites across North America. Closely comparable to Accel in site-network model, therapeutic breadth, and AMRC-era multisite positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Accel Research Sites

Clinical Research Servicesaccelresearchsites.com

Accel Research Sites (dba Alcanza Clinical Research) operates a 26+ location network of multi-therapeutic clinical research sites across the US and Puerto Rico, serving pharmaceutical sponsors and CROs with patient recruitment, trial execution, and the ReachOne AI Toolbox.

What Accel Research Sites does

Accel Research Sites, doing business as Alcanza Clinical Research, is a private clinical research site network founded in 1998 and headquartered in Florida. The company operates 26+ dedicated clinical research facilities across the Southeast, Northeast, Midwest, and Southwest United States, plus Puerto Rico (Mayagüez and San Juan), providing trial execution services in more than 30 therapeutic areas including Alzheimer's disease, oncology, diabetes, vaccines, dermatology, cardiology, and women's health. Accel serves two primary customer segments: pharmaceutical sponsors and Contract Research Organizations (CROs), which contract the network to conduct clinical trials; and patient volunteers, who are recruited through a community-based GTM model that combines website registration, medical provider referrals, and outreach to community-based organizations. The company emphasizes inclusive research participation across diverse demographic populations, supported by multilingual website access in eight languages (English, Spanish, French, German, Italian, Dutch, Chinese, and Arabic).

The company's core technology is the ReachOne AI Toolbox, a wholly-owned subsidiary product positioned as an AI-powered platform for clinical research operations with integration/interoperability as its cited differentiator. ReachOne supplements the primary professional-services revenue stream, which is generated through per-study fees from sponsors and CROs for patient recruitment, study execution, and data collection. Accel is a founding member of the Association of Multisite Research Corporations (AMRC), launched in 2024 as a 14-organization alliance encompassing 400+ research sites, nearly 1,000 Principal Investigators, and more than 7,000 research professionals that collectively enrolled over 73,500 patients in 2024. No external funding rounds, M&A activity, or institutional ownership are disclosed in the available source material, and the company appears to operate as an independently-run private entity.

Accel Research Sites firmographics

Firmographics
Name
Accel Research Sites
Legal name
Accel Research Sites
Website
https://accelresearchsites.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
51–100 employees
Short description
Accel Research Sites (dba Alcanza Clinical Research) operates a 26+ location network of multi-therapeutic clinical research sites across the US and Puerto Rico, serving pharmaceutical sponsors and CROs with patient recruitment, trial execution, and the ReachOne AI Toolbox.
Ownership category
akta.pro rank

Accel Research Sites industry classification

Industry
Product category
Clinical Research Services
NAICS
Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Clinical research services
  • Clinical trial network
  • Multisite research
  • Patient recruitment
  • Therapeutic trials

Where Accel Research Sites is headquartered

Location

Headquarters

HQ city
Lake Mary
HQ country
United States
HQ region
North America

Offices31 records

Markets served

Accel Research Sites business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Clinical Research Services: Revenue generated from conducting clinical trials on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). Services include patient recruitment, study execution, and data collection for drug development programs.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPatient volunteer compensation for participation

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Accel Research Sites product offering

Product offering

Core offering

Accel Research Sites (operating as Alcanza Clinical Research) is a multi-therapeutic network of dedicated clinical research sites that conduct clinical trials on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). The company delivers patient recruitment, study execution, and data collection services across a broad range of therapeutic areas, including Alzheimer's, diabetes, vaccines, oncology, and chronic conditions, through a community-based model spanning 26+ dedicated research facilities across the United States and Puerto Rico.

Product overview

Alcanza Clinical Research operates as a clinical research site network offering a unified platform for clinical trial participation. The core product is their clinical research services network, supplemented by the ReachOne AI Toolbox for technology-enabled research capabilities. They provide local communities with opportunities to participate in clinical research at dedicated facilities across multiple states, collaborating with medical providers and community organizations.

Differentiator

Problem solved

Functional benefit

Brands

  • ReachOne AI Toolbox: AI-powered clinical research tools and platform technology

Products and services

  • Alcanza Clinical Research Clinical research site network providing health education and clinical research participation options to diverse patient populations across multiple therapeutic areas. Operates dedicated clinical research facilities across the United States and Puerto Rico, collaborating with medical providers and community-based organizations to deliver clinical trial opportunities for pharmaceutical sponsors and CROs.

Quantifiable outcome

  • 73,500 patients enrolled in clinical trials in 2024 through AMRC network

Companies that use Accel Research Sites

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Accel Research Sites technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Accel Research Sites partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Association of Multisite Research Corporations (AMRC)coreStrategic or Co-development Partner · 1 January 2024Alcanza Clinical Research is a founding member of AMRC, a newly launched alliance of 14 prominent multisite research organizations. AMRC aims to transform clinical trial operations across the U.S. with a network of over 400 research sites, nearly 1,000 Principal Investigators, and over 7,000 research professionals. In 2024, AMRC members collectively enrolled over 73,500 patients into clinical trials. The alliance focuses on minimizing delays impacting 80% of clinical trials, improving operational efficiency, and strengthening collaboration and data quality.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Accel Research Sites competitors and assessment

Company assessment

Direct peers

  • Flourish Research: Multisite clinical research organization operating dedicated research facilities with multi-therapeutic enrollment. Directly comparable SMO competing in the same sponsor-RFP environment as Accel Research Sites.
  • Velocity Clinical Research: Multi-therapeutic integrated clinical research site network operating dedicated research facilities across the US. Directly comparable to Accel on SMO business model, multi-therapeutic scope, geographic dispersion, and sponsor/CRO customer base.
  • Worldwide Clinical Trials: Mid-size global CRO with site-management and clinical operations offerings. Comparable to Accel on customer base (small-to-mid-biotech sponsors), therapeutic breadth, and professional-services revenue model.
  • Clinipace Worldwide: Mid-size full-service CRO with embedded site management capabilities, serving similar small-to-mid-biotech sponsors as Accel. Comparable on therapeutic scope, sponsor-customer profile, and clinical operations delivery model.
  • Centricity Research: Integrated multi-specialty clinical research site organization running dedicated Phase I-IV sites across North America. Closely comparable to Accel in site-network model, therapeutic breadth, and AMRC-era multisite positioning.

Broad incumbents

  • ICON plc: Global CRO with site-management, clinical operations, and lab services at scale. Competes head-to-head with Accel for site-network selection on multi-region sponsor trials, though from a much broader service portfolio.
  • Medpace: Mid-to-large CRO specializing in operational delivery of clinical trials across therapeutic areas. Comparable on the clinical-operations and Phase II/III execution layer where Accel provides site capacity, but operates without a dedicated owned-site footprint of Accel's scale.
  • IQVIA: Largest global CRO with an integrated site-management and clinical operations platform. Overlaps with Accel on clinical research service delivery but competes from full-service portfolio leverage — directly bidding against Accel for sponsor master agreements.
  • Parexel International: Global CRO offering clinical operations, site management, regulatory, and biopharma services. Comparable to Accel on the sponsor-customer side and on clinical trial execution, though from a far broader full-service delivery model.
  • Syneos Health: Global CRO with embedded site-network and decentralized-trial capabilities. Comparable across clinical operations and site management, broader portfolio across commercial and consulting services beyond Accel's narrower SMO scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Accel Research Sites financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Accel Research Sites leadership team

Management profile

Number of profiles

Accel Research Sites subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Accel Research Sites funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Accel Research Sites M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accel Research Sites

What does Accel Research Sites do?

Accel Research Sites (operating as Alcanza Clinical Research) is a multi-therapeutic network of dedicated clinical research sites that conduct clinical trials on behalf of pharmaceutical sponsors and Contract Research Organizations (CROs). The company delivers patient recruitment, study execution, and data collection services across a broad range of therapeutic areas, including Alzheimer's, diabetes, vaccines, oncology, and chronic conditions, through a community-based model spanning 26+ dedicated research facilities across the United States and Puerto Rico.

Is Accel Research Sites a public or private company?

Accel Research Sites is a private company. It is classified as unknown and is currently operating.

When was Accel Research Sites founded?

Accel Research Sites was founded in 1998. It employs 51 to 100 people.

Where is Accel Research Sites based?

Accel Research Sites is headquartered in Lake Mary, United States, in the North America region.

How does Accel Research Sites make money?

One revenue line is on record: clinical Research Services.

Who are Accel Research Sites's main competitors?

Direct peers on record are Flourish Research, Velocity Clinical Research, Worldwide Clinical Trials, Clinipace Worldwide and Centricity Research. Broad incumbents are ICON plc, Medpace, IQVIA, Parexel International and Syneos Health.

Does Accel Research Sites have an API?

No public API is recorded for Accel Research Sites.

What industry is Accel Research Sites in?

Accel Research Sites's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAC, Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts), with a secondary code of HLAGAAAI, Patient Recruitment, Site Feasibility & Trial Enablement CROs. Its NAICS code is 54169 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRLogAccel Research Sites recruiting smokers for cessation studyAccel Research Sites is recruiting current daily smokers aged 18 and older for a clinical trial at its DeLand site. The trial tests an investigational pill that mimics nicotine to reduce withdrawal side effects, with participants monitored for 24 weeks and compensated. Eligible participants have a two-in-three chance of receiving the medicine.PRLogAccel Research Sites now enrolling healthy volunteers, 60 to 80 years old, for phase 1 trialAccel Research Sites is enrolling 25 healthy men and 25 healthy women aged 60-80 for a phase 1 trial at its DeLand location. The study tests an investigational therapeutic for idiopathic pulmonary fibrosis and other lung conditions, including Long COVID. The trial begins November 13, 2021.PRLogAccel Research Sites now recruiting for schizophrenia clinical trialAccel Research Sites in Lakeland is recruiting participants for a clinical trial of an Avanir Pharmaceuticals drug targeting negative symptoms of schizophrenia. The trial seeks patients aged 18-60 on second-generation antipsychotics with persistent negative symptoms, lasting six months with seven visits and a placebo group.PRLogAccel Research Sites selected for COVID-19 treatment trialsAccel Research Sites will begin three clinical trials for Pfizer's oral antiviral at its St. Petersburg site, led by Dr. Hiten Upadhyay. The trials target high-risk, lower-risk, and close-contact patients, enrolling 3,000-4,000 adults over several months. Recruitment starts soon, with the study commencing later this month.PR NewswireAccel Research Sites Announces Appointment of New CEOAccel Research Sites announced the appointment of Matthew Maxwell as Chief Executive Officer, effective April 19, 2019. Maxwell brings over 12 years of clinical research leadership experience, having most recently served as the company's Chief Operating Officer. He stated his intention to drive growth of the research network to expand treatment options available to patients and providers in the communities they serve.